Set a Scientific Meeting Agenda With Clear Role Boundaries

A department chair calls to set up a scientific meeting with several clinicians in the department. They want it to be useful, but they are not fully sure what useful means for a medical science liaison, and they may lump scientific questions together with practical ones about access and formulary status. If you do not set the agenda yourself before the meeting happens, the conversation can drift into promotional territory or turn into an access negotiation with the wrong people in the room. Setting clear boundaries early protects the science, protects the group's time, and protects you.

Why This Conversation Goes Wrong

Physicians who request a meeting often think in practical terms, not in terms of role definitions. They want to know how a drug performed in a trial, but they also want to know if it is on formulary, whether samples are available, and who from the company can help with access questions. To them, this all feels like one conversation, since they are simply trying to solve a problem for their patients. Your role covers the scientific and clinical questions only. Sales and market access sit in a different function for good reason. When you accept a vague meeting invitation without clarifying scope in advance, you risk fielding the wrong kind of question in the room, or worse, letting a commercial topic slide into a session that is supposed to be scientific exchange.

This is not a small technicality. Compliance structures exist because these conversations blur together easily, and a chair who is used to dealing with a sales representative may have no idea that a boundary exists at all. On top of that, a vague agenda wastes everyone's time. Clinicians show up expecting real answers to real questions, and if the conversation meanders, they leave without what they came for, and your credibility with that account takes the hit.

How to Prepare

Before you agree to a date, ask the chair to name the two or three scientific or clinical questions the group actually wants addressed. Ask whether they want to review specific published studies, understand a mechanism of action, or talk through data from a particular trial. Ask how much time is available and roughly how many clinicians will attend. These answers tell you what to prepare and whether you need to check anything with medical affairs before the meeting happens.

Put the scope in writing, even a short email restating the two or three topics and confirming that the session is a scientific exchange, not a promotional or access discussion, protects you if anyone questions the meeting's content later. If the chair mentions wanting someone from sales or access to join, treat that as a separate request entirely, one that deserves its own meeting with the right people rather than a seat at your table.

If any of the questions touch on gaps or limitations in the published data, prepare to address those honestly rather than smoothing them over. The post on how to Discuss a Published Study's Limitations With Care covers how to answer a pointed question about study design without overstating or underselling what the evidence actually shows.

What to Say

Open the planning call with a direct question, then hold your ground when the conversation drifts toward access or logistics.

The chair says, "We have five physicians who want to hear about your new agent. Can someone from sales join us to talk about formulary access while everyone is already in the room?"

You respond, "For the scientific session, I want to keep the agenda focused on the clinical questions your group has. I can set up a separate conversation with the account team to cover access, so nobody has to wait on that. What are the two or three questions your physicians most want answered?"

The chair says, "They want to know how the drug compared to standard of care across the two pivotal trials, and whether there is any data yet in patients with renal impairment."

From there, you confirm you can bring the primary publications for both trials and check what exists on renal impairment, flagging plainly if the data is thin rather than filling the gap with speculation. You offer forty five minutes for the scientific session and ask if that works. The chair agrees to the time and the two topics.

Notice what happened. You answered a logistics question with a boundary, then moved straight to specifics instead of lecturing the chair about why the boundary exists. You gave the access request a real path forward instead of just declining it, and you made progress on the scientific agenda in the same breath.

Mistakes to Avoid

Do not let the chair set an open ended agenda. An invitation to talk about the drug in general gives you nothing to prepare against and no way to judge afterward whether you actually answered well.

Do not let a sales or access colleague join the scientific portion of the meeting, even for a few minutes. Once a commercial colleague is in the room, the character of the meeting changes, and you lose the ability to describe the session cleanly as scientific exchange if anyone ever asks.

Do not promise data you have not personally checked. If a chair asks about a subgroup or a comparison you have not reviewed, say you will check and follow up rather than guessing out loud in front of five physicians.

Do not skip the written confirmation of scope because the request seems simple or the chair seems busy. A short email restating the topics and the time limit takes two minutes and removes ambiguity that would otherwise surface later, often at a worse moment.

Do not assume every question that comes up during a scientific meeting is automatically fair game just because the meeting is scientific. A question about use outside the approved label deserves its own careful handling, and the post on how to Handle an Unsolicited Scientific Question About Use Outside Approved Labeling walks through how to respond when a physician raises exactly that.

How to Practice and Score It

A manager reviewing this skill should watch for three things. Did the MSL ask for specific questions before agreeing to a broad topic. Did the MSL redirect the access request without sounding defensive or delivering a compliance lecture. Did the MSL confirm scope in a form the chair could actually act on, meaning a short list of topics and a clear time limit.

Rehearsing this call before it happens beats reviewing it after the fact. DealSpeak lets you run this exact scenario, a chair proposing a mixed meeting with both scientific and access elements, and see how well you separate the two in real time under a scoring model built for this kind of conversation. You can find it under Pharmaceuticals practice conversations and get direct feedback on where the boundary held and where it slipped.

Running through this scenario a few times before a real planning call makes the redirect automatic instead of something you have to invent on the spot, with a busy chair on the line and five physicians waiting on a date.

Where This Leaves You

A scientific meeting stays useful and stays clean when you name the questions in advance and send everything else somewhere else. The chair gets a focused session, the physicians get real answers, and you avoid the gray area that causes problems months later when someone asks what actually happened in that room.